Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CARBIDOPA, LEVODOPA AND ENTACAPONE TABLETS safely and effectively. See full prescribing information for CARBIDOPA, LEVODOPA AND ENTACAPONE TABLETS.CARBIDOPA, LEVODOPA AND ENTACAPONE tablets, for oral use Initial U.S. Approval: 2003
Medication labelWhy this: Advisory · dailymed-prescription
Carbidopa, levodopa and entacapone tablets, is indicated for the treatment of Parkinson’s disease. Carbidopa, levodopa and entacapone tablets can be used: To substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products. To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearing-off” and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias.
- generic_name
- carbidopa, levodopa and entacapone
- product_names
- Carbidopa, Levodopa and Entacapone
- ndc
- 33342-491, 33342-492, 33342-493, 33342-494, 33342-495, 33342-496, 33342-491-11, 33342-491-12, 33342-492-11, 33342-492-12, 33342-493-11, 33342-493-12, 33342-494-11, 33342-494-12, 33342-495-11, 33342-495-12, 33342-496-11, 33342-496-12
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en